Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus.
Eveline BruinstroopLaura MeyerCatherine B BrouwerDiana E van RooijenP Sytze van DamPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2018)
The majority of patients continued liraglutide after a switch from insulin therapy with on average no change in glycemic control and decrease of body weight. HbA1c levels at baseline, duration of insulin therapy, and duration of diabetes were predictive of reaching glycemic control on liraglutide alone. In current practice this also indicates which patients on insulin can reduce their insulin dose after adding a GLP-1 receptor agonist. Plain language summary available for this article.
Keyphrases
- glycemic control
- type diabetes
- blood glucose
- end stage renal disease
- weight loss
- chronic kidney disease
- ejection fraction
- body weight
- insulin resistance
- newly diagnosed
- peritoneal dialysis
- primary care
- cardiovascular disease
- autism spectrum disorder
- healthcare
- mesenchymal stem cells
- metabolic syndrome
- bone marrow
- stem cells
- patient reported outcomes
- replacement therapy